[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Fan DM, Shi HR, Chen ZM, Liu HN, Zhang RT: [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1355-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of TGF-beta1 and E-cadherin in primary and metastatic ovarian carcinoma].
  • OBJECTIVE: To detect the expression of the protein of TGF-beta1 and E-cadherin in the primary and metastatic lesions of ovarian carcinoma and explore the mechanism of the metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry (IHC) was performed to detect the expression of TGF-beta1 and E-cadherin proteins in primary and metastatic ovarian carcinoma, benign epithelial ovarian tumor and normal ovarian tissue.
  • RESULTS: The expression of TGF-beta1 was significantly higher in ovarian carcinoma (67.2%) than in benign tumors (28.6%) and normal ovarian tissue (18.9%) (Chi2=26.94, P<0.001), but E-cadherin expression showed a reverse pattern.
  • TGF-beta1 expression in the primary ovarian carcinoma carcinoma was associated with the FIGO stage, lymph metastasis and ascites of the tumor (P=0.01, P=0.01, and P=0.04, respectively).
  • E-cadherin expression in the tumor was associated with the differentiation (P=0.02) and lymph metastasis of ovarian carcinoma (P=0.04).
  • The expressions of TGF-beta1 and E-cadherin were all significantly lower in the primary tumors than in the metastatic tumor (Chi2=4.70, P=0.03; Chi2=5.91, P=0.015).
  • CONCLUSION: TGF-beta1 and E-cadherin are closely associated with the metastasis of ovarian carcinoma and might be potential targets for controlling the metastasis of ovarian carcinoma.
  • [MeSH-major] Cadherins / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584638.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDH1 protein, human; 0 / Cadherins; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


2. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC: Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol; 2005 Jan;96(1):77-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
  • OBJECTIVE:. (1) To identify and (2) validate genes that are up-regulated in ovarian cancer, and (3) to investigate whether the activity of a candidate gene, creatine kinase B (CKB) is elevated in pre-operative sera from ovarian cancer patients compared to patients with benign pelvic masses and normal controls.
  • METHODS: MICROMAX cDNA microarray system and RNA derived from pooled ovarian cancer cell lines and normal ovary surface epithelial cells (HOSE) were used to identify differentially expressed genes.
  • Using a commercially available enzyme assay, CKB activity was measured in pre-operative serum samples obtained from 45 ovarian cancer patients, 49 patients with a benign pelvic mass, as well as 37 normal controls.
  • RNA levels of CKB, measured by real-time PCR, were elevated a mean (and standard error) of 36-fold (8.4) in cancer cell lines compared with HOSE cells and 22.75-fold (10.45) in microdissected ovarian cancer epithelial cells compared with normal ovarian epithelial cells.
  • In serum, the mean (+/-standard error) of CKB enzyme activity in cancer cases was 24.7 U/L units (+/- 5.1) compared to 9.6 U/L (+/- 1.6) for benign mass cases (P = 0.0088) and to 8.5 U/L (1.7) for normal controls (P = 0.0096).
  • CONCLUSIONS: Microarray technology offers a method to identify tumor biomarkers with potential clinical usefulness.
  • Our data indicated that CKB gene expression is up-regulated in ovarian cancer cells in vitro and in vivo and that CKB enzyme activity is significantly elevated in sera from ovarian cancer patients, including those with stage I disease.
  • These findings suggest a potential role for CKB as a marker for early diagnosis.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Creatine Kinase / biosynthesis. Isoenzymes / biosynthesis. Oligonucleotide Array Sequence Analysis / methods. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Creatine Kinase, BB Form. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589584.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86381; United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Neoplasm; EC 2.7.3.2 / Creatine Kinase; EC 2.7.3.2 / Creatine Kinase, BB Form
  •  go-up   go-down


3. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • The sectioned surface was solid in 9, solid-cystic in 15, and multicystic in 5.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Nonmucinous carcinomatous components included adenocarcinoma with high-grade endometrioid-like morphology in 2 cases, papillary adenocarcinoma simulating mixed müllerian epithelial adenocarcinoma in 1, and undifferentiated carcinoma in 2.
  • The high rate of bilaterality, surface involvement, multinodular growth, and heterogeneity of patterns were the most helpful features for indicating a metastatic nature, with signet ring cells also being helpful in the minority of cases in which they were present.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL: Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res; 2010;3:28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.
  • BACKGROUND: We showed there are specific ALDH1 autoantibodies in ovarian autoimmune disease and ovarian cancer, suggesting a role for ALDH1 in ovarian pathology.
  • However, there is little information on the ovarian expression of ALDH1.
  • Therefore, we compared ALDH1 expression in normal ovary and benign and malignant ovarian tumors to determine if ALDH1 expression is altered in ovarian cancer.
  • Since there is also recent interest in ALDH1 as a cancer stem cell (CSC) marker, we assessed co-expression of ALDH1 with CSC markers in order to determine if ALDH1 is a potential CSC marker in ovarian cancer.
  • METHODS: mRNA and protein expression were compared in normal human ovary and serous ovarian tumors using quantitative Reverse-Transcriptase PCR, Western blot (WB) and semi-quantitative immunohistochemistry (IHC).
  • ALDH1 enzyme activity was confirmed in primary ovarian cells by flow cytometry (FC) using ALDEFLUOR assay.
  • RESULTS: ALDH1 mRNA expression was significantly reduced (p < 0.01; n = 5) in malignant tumors compared to normal ovaries and benign tumors.
  • The proportion of ALDH1+ cells was significantly lower in malignant tumors (17.1 ± 7.61%; n = 5) compared to normal ovaries (37.4 ± 5.4%; p < 0.01; n = 5) and benign tumors (31.03 ± 6.68%; p < 0.05; n = 5).
  • ALDH1+ cells occurred in the stroma and surface epithelium in normal ovary and benign tumors, although surface epithelial expression varied more in benign tumors.
  • Localization of ALDH1 was heterogeneous in malignant tumor cells and little ALDH1 expression occurred in poorly differentiated malignant tumors.
  • In benign tumors the distribution of ALDH1 had features of both normal ovary and malignant tumors.
  • CONCLUSIONS: Total ALDH1 expression is significantly reduced in malignant ovarian tumors while it is relatively unchanged in benign tumors compared to normal ovary.
  • Thus, ALDH1 expression in the ovary does not appear to be similar to breast, lung or colon cancer suggesting possible functional differences in these cancers.
  • SIGNIFICANCE: These observations suggest that reduced ALDH1 expression is associated with malignant transformation in ovarian cancer and provides a basis for further study of the mechanism of ALDH1 in this process.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Immunol. 2009 Feb;21(1):22-7 [18778953.001]
  • [Cites] Mol Cancer. 2008;7:87 [19025616.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1144-53 [19293794.001]
  • [Cites] Fertil Steril. 2010 Dec;94(7):2636-41 [20522323.001]
  • [Cites] Int J Cancer. 1994 Mar 1;56(5):743-8 [8314353.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):1-20 [10942515.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3638-45 [11014218.001]
  • [Cites] Cancer Res. 2000 Dec 1;60(23):6744-9 [11118061.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Chem Biol Interact. 2003 Feb 1;143-144:201-10 [12604205.001]
  • [Cites] J Biochem Mol Toxicol. 2003;17(1):7-23 [12616643.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1013-20 [12631600.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1648-55 [15178579.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] FASEB J. 1991 Nov;5(14):2924-33 [1661245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1092-100 [16969345.001]
  • [Cites] J Immunol. 2007 Sep 15;179(6):3724-33 [17785809.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10538-45 [17974998.001]
  • [Cites] J Cell Sci. 1991 Nov;100 ( Pt 3):657-66 [1808213.001]
  • [Cites] Cell Stem Cell. 2007 Nov;1(5):555-67 [18371393.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] Mol Cancer Res. 2008 Jul;6(7):1146-53 [18644979.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):2236-52 [18681906.001]
  • [Cites] Int Immunol. 2009 Apr;21(4):361-77 [19190084.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Birth Defects Res C Embryo Today. 2009 Mar;87(1):64-89 [19306350.001]
  • [Cites] Mod Pathol. 2009 Jun;22(6):817-23 [19329942.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3382-9 [19336570.001]
  • [Cites] Nucl Recept Signal. 2009;7:e002 [19381305.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Aug;123(1):109-11 [19946740.001]
  • [Cites] Lab Invest. 2010 Feb;90(2):234-44 [20010854.001]
  • [Cites] Clin Cancer Res. 2010 Feb 1;16(3):876-87 [20103682.001]
  • [Cites] PLoS One. 2010;5(4):e10277 [20422001.001]
  • [Cites] Cell Commun Signal. 2010;8(1):6 [20459772.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 18;87(2):146-7 [7707390.001]
  • [Cites] Neurobiol Aging. 1993 Jul-Aug;14(4):275-85 [8367009.001]
  • [Cites] Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S52-62 [8811064.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):54-62 [9103391.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2033-8 [9815594.001]
  • [Cites] J Investig Med. 1996 Feb;44(2):42-6 [8689400.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2157-63 [12727970.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Mol Cancer. 2004 Oct 7;3:27 [15471544.001]
  • [Cites] J Endocrinol. 2004 Oct;183(1):19-28 [15525570.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):138-43 [16004729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11707-12 [16857736.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Jul;72(4):281-9 [17111384.001]
  • [Cites] Lung Cancer. 2008 Mar;59(3):340-9 [17920722.001]
  • [Cites] Toxicol Sci. 2008 Jan;101(1):51-64 [17998271.001]
  • [Cites] Endocrinology. 2008 Sep;149(9):4307-11 [18556344.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):697-720 [18611112.001]
  • (PMID = 21176222.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022900
  •  go-up   go-down


5. Rosen DG, Yang G, Bast RC Jr, Liu J: Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol; 2006;407:660-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer.
  • The Ras gene family has been implicated in the development of many human epithelial cancers.
  • Mutations in K-ras or its downstream mediator BRAF have been detected in about two thirds of low-grade serous carcinomas and borderline serous tumors; mutations in K-ras are also often present in benign and invasive mucinous ovarian cancers.
  • Although the oncogenic allele H-ras(V12) is present in only approximately 6% of ovarian cancers, physiologically activated H-ras protein is commonly detected in human ovarian cancer, presumably because of an increase in upstream signals from tyrosine kinase growth factor receptors such as Her-2/neu, despite the lack of a Ras mutation.
  • The mechanisms by which ras oncogenes transform human epithelial cells are not clear.
  • The methods described here are what we use to culture human ovarian surface epithelial cells, to immortalize those cells, and to transform the immortalized cells with oncogenic H-ras or K-ras.
  • These Ras-transformed human ovarian surface epithelial cells form tumors in nude mice and recapitulate many features of human ovarian cancer, thus providing an excellent model system for studying the initiation and progression of human ovarian cancer.
  • [MeSH-major] Cell Transformation, Neoplastic. Oncogene Protein p21(ras) / pharmacology. Ovarian Neoplasms / physiopathology. Ovary / cytology
  • [MeSH-minor] Animals. Antigens, Viral, Tumor / pharmacology. Cells, Cultured. Epithelial Cells / drug effects. Female. Humans. Immunohistochemistry. Mice. Mice, Nude. Simian virus 40 / immunology. Telomerase / pharmacology. Transfection


6. Rajesh NG, Rekha K, Krishna B: Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation. Indian J Pathol Microbiol; 2007 Apr;50(2):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of p53 expression in ovarian tumors and its correlation to the morphological differentiation.
  • Interestingly the ovarian cancer has the highest mortality rate.
  • This is attributed to its late clinical presentation and delayed diagnosis.
  • The expression of p53 throws light on the prognosis of ovarian tumors.
  • The surface epithelial tumors, especially the serous cystadenocarcinoma and non Hodgkin lymphoma of ovary where in the expression p53 was high compared to the benign and borderline tumors.
  • Further the expression of p53 in tumors arising from germinal cells, sex-cord stromal cells are observed to be very low.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883046.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Lin CH, Liu FS, Ho ES: Transitional cell carcinoma of the ovary. Taiwan J Obstet Gynecol; 2006 Sep;45(3):268-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ovary.
  • OBJECTIVE: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian surface epithelial cancer.
  • We present a case of TCC of the ovary, managed by staging operation and followed by postoperative chemotherapy with carboplatin and cyclophosphamide.
  • After surgery, the pathologic report of the left ovarian tumor was TCC, grade 2-3, stage IA.
  • CONCLUSION: TCC of the ovary is a rare subtype of epithelial ovarian cancer.
  • It differs from malignant Brenner tumor by the absence of a benign or borderline Brenner component.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of common epithelial ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy


8. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem; 2010 Nov;58(11):1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.
  • Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian tumors has not been described.
  • Here, we investigated the expression of SAA in human benign and malignant ovarian epithelial tumors.
  • Non-radioactive in situ hybridization applied on ovarian paraffin tissue sections revealed mostly negative SAA mRNA expression in normal surface epithelium.
  • Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
  • RT-PCR analysis confirmed the overexpression of the SAA1 and SAA4 genes in ovarian carcinomas compared with normal ovarian tissues.
  • In addition, strong expression of SAA mRNA and protein was found in the ovarian carcinoma cell line OVCAR-3.
  • Finally, patients with ovarian carcinoma had high SAA serum levels, which strongly correlated with high levels of CA-125 and C-reactive protein.
  • Enhanced expression of SAA in ovarian carcinomas may play a role in ovarian tumorigenesis and may have therapeutic application.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]
  • [Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]
  • [Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]
  • [Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]
  • [Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]
  • [Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]
  • (PMID = 20713982.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2958134
  •  go-up   go-down


9. Zhang SL, Yu Y, Jiang T, Lin B, Gao H: [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi; 2005 Oct;40(10):689-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of KiSS-1 and its receptor GPR54 mRNA in epithelial ovarian cancer].
  • OBJECTIVE: To study the expression and significance of metastasis suppressor gene KiSS-1 and its receptor GPR54 in epithelial ovarian cancer.
  • METHOD: The expression and their clinical significance of KiSS-1 and GPR54 were evaluated by RT-PCR in 37 patients with epithelial ovarian cancer, 15 patients with borderline epithelial ovarian tumors, 15 patients with epithelial benign tumors and 11 patients with normal ovarian tissues.
  • RESULTS: The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer (68%, 0.82 +/- 0.09) and borderline epithelial ovarian tumors (60%, 0.80 +/- 0.10) were all higher than in patients with epithelial benign tumor (20%, 0.65 +/- 0.10) and normal ovarian tissues (18%, 0.66 +/- 0.06; P < 0.05).
  • The positivity and relative contents of KiSS-1 mRNA in patients with epithelial ovarian cancer correlated with their clinical stage and lymph node metastasis (P < 0.05).
  • There was no difference in the positivity and relative contents of GPR54 mRNA between patients with epithelial ovarian cancer (70%, 0.79 +/- 0.07), borderline epithelial ovarian tumor (67%, 0.76 +/- 0.10), benign epithelial ovarian tumor (60%, 0.73 +/- 0.07) and normal ovarian tissues (45%, 0.78 +/- 0.08), respectively (all P > 0.05).
  • The positivity and relative contents of GPR54 mRNA in patients with epithelial ovarian cancer did not correlate with their clinical stage, histology grade, lymph node metastasis and production of ascites (P > 0.05).
  • CONCLUSION: KiSS-1 and GPR54 may play an important role in inhibiting the invasion and metastasis of early epithelial ovarian cancer.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / pathology. Receptors, G-Protein-Coupled / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Kisspeptins. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277902.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / KISS1R protein, human; 0 / Kisspeptins; 0 / RNA, Messenger; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


10. Shi HR, Zhang RT: [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer]. Ai Zheng; 2009 Aug;28(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer].
  • This study was to investigate the expression and significance of P53, P21WAF1 and CDK1 proteins in epithelial ovarian cancer.
  • METHODS: The expression of P53, P21WAF1 and CDK1 proteins in 20 specimens of normal ovarian tissues, 20 specimens of benign epithelial ovarian tumor and 76 specimens of epithelial ovarian cancer was detected by immunohistochemistry.
  • Their correlations to the clinicopathologic characteristics of epithelial ovarian cancer and their interrelationships were analyzed.
  • RESULTS: Significant differences were noted in the positive rates of P53, P21WAF1 and CDK1 proteins between epithelial ovarian cancer and normal ovarian tissues, benign ovarian tumors (P < 0.05).
  • In epithelial ovarian cancer, up-regulation of P53 protein was associated with advanced FIGO stage and poor differentiation; down-regulation of P21WAF1 protein was associated with advanced FIGO stage; CDK1 showed no association with any clinicopathologic factors.
  • CONCLUSIONS: P53 protein is related to the malignancy of epithelial ovarian cancer, P53 and P21WAF1 protein may be related to the malignant development of epithelial ovarian cancer.
  • CDK1 detection may be helpful in the early diagnosis of epithelial ovarian cancer.
  • [MeSH-major] CDC2 Protein Kinase / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664338.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.22 / CDC2 Protein Kinase
  •  go-up   go-down


11. Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM: Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res; 2005 May 1;65(9):3726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis.
  • Epithelial ovarian cancer derived from the human ovarian surface epithelium (HOSE) is the leading cause of death from gynecologic malignancies among American women.
  • In this study, we showed overexpression of CYP1A1 mRNA, but not CYP1B1 transcripts, in ovarian cancer cell lines when compared with primary cultures or immortalized HOSE cell lines.
  • CYP1A1v is overexpressed in ovarian cancer cell lines and exhibits a unique subcellular distribution restricted to the nucleus and mitochondria, contrary to the endoplasmic reticulum localization of the wild-type enzyme.
  • In concordance, total CYP1A1 activity, as measured by the ethoxyresorufin O-deethylase assay, was detected in mitochondrial, nuclear, and microsomal fractions of ovarian cancer cells but was notably absent in all subcellular fractions of HOSE cells.
  • Immunocytochemistry studies in 30 clinical specimens revealed overexpression of CYP1A1 in various types of ovarian cancers compared with benign epithelia and frequent localization of the enzyme to cancer cell nuclei.
  • Collectively, these data provided the first evidence that CYP1A1 overexpression and alternative splicing could contribute to ovarian cancer initiation and progression.
  • [MeSH-major] Cytochrome P-450 CYP1A1 / biosynthesis. Cytochrome P-450 CYP1A1 / genetics. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Base Sequence. Benzo(a)pyrene / pharmacokinetics. Carcinogens / pharmacokinetics. Cell Line, Tumor. Cell Nucleus / enzymology. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Epithelium / enzymology. Epithelium / pathology. Estradiol / pharmacokinetics. Female. Humans. Isoenzymes. Mitochondria / enzymology. Molecular Sequence Data. Ovary / cytology. Ovary / drug effects. Ovary / enzymology. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Subcellular Fractions / enzymology. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867368.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA94221
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Isoenzymes; 0 / RNA, Messenger; 3417WMA06D / Benzo(a)pyrene; 4TI98Z838E / Estradiol; EC 1.14.14.1 / Cytochrome P-450 CYP1A1
  •  go-up   go-down


12. Cody NA, Shen Z, Ripeau JS, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN: Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer. Mol Carcinog; 2009 Dec;48(12):1077-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.
  • The genetic analysis of nontumorigenic radiation hybrids generated by transfer of chromosome 3 fragments into the tumorigenic OV-90 ovarian cancer cell line identified the 3p12.3-pcen region as a candidate tumor suppressor gene (TSG) locus.
  • The expression of all but one (VGLL3) of these genes was also detected in the parental OV-90 cell line.
  • Mutations were not identified in a comparative sequence analysis of the predicted protein coding regions of these candidates in OV-90 and donor normal chromosome 3 contig.
  • Interestingly, underexpression of VGLL3 and ZNF654 were observed in malignant ovarian tumor samples as compared with primary cultures of normal ovarian surface epithelial cells or benign ovarian tumors, and this occurred regardless of allelic content of 3p12.3-pcen.
  • The results taken together suggest that dysregulation of VGLL3 and/or ZNF654 expression may have affected pathways important in ovarian tumorigenesis which was offset by the transfer of chromosome 3 fragments in OV-90, a cell line hemizygous for 3p.
  • [MeSH-major] Chromosomes, Human, Pair 3 / genetics. Cystadenocarcinoma, Serous / genetics. Genes, Tumor Suppressor / physiology. Ovarian Neoplasms / genetics
  • [MeSH-minor] Alternative Splicing. Case-Control Studies. Cell Line, Tumor. DNA Methylation. DNA Primers / chemistry. DNA Primers / genetics. Female. Humans. Loss of Heterozygosity. Microsatellite Repeats. Ovary / metabolism. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347865.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


13. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ: Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol; 2009 Dec;33(12):1878-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Risk-reducing salpingo-oophorectomy (RRSO) significantly lowers the incidence of ovarian, tubal, peritoneal, and breast cancer in women who carry BRCA1 or BRCA2 germline mutations.
  • Recommended protocols to maximize tumor detection emphasize the role of thinly slicing the tubes and ovaries and embedding the entire specimen for microscopic examination.
  • Clinically occult carcinoma ranging in size from 1 to 13 mm was initially detected in 11 of 102 women (5 in tubal fimbriae only, 1 in tubal isthmus only, 2 in fimbriae and ovary, and 3 in ovary only).
  • No tubal carcinoma was identified in the level sections of any case originally classified as benign.
  • Clinical follow-up among women with benign RRSO findings revealed that 2 women subsequently developed peritoneal carcinomatosis at 22 and 62 months postoperatively.
  • Retrospective exhaustive multistep level sectioning of all remaining tubal and ovarian blocks from both these women confirmed the original benign diagnosis in 1 woman but in the other woman, the deepest levels of 1 ovarian block revealed a single 1-mm nodule of cancer at the base of an ovarian surface epithelial invagination.
  • This specimen was one of the first RRSO cases in our experience and on review of the original report, this ovary was not dissected into multiple slices along its short axis but was only bivalved along its long axis.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898224.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


14. Zhou JW, Gan NY, Zhang WJ: [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues]. Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Jun;42(3-4):224-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of MKP-1 and p-ERK(1/2) in primary ovarian epithelial tumor tissues].
  • To investigate the expression of mitogen activated protein kinase phosphatase-1 (MKP-1) and phosphorylation extracellular signal-regulated kinases (p-ERK(1/2)) in primary ovarian epithelial tumor tissues, and provide experiment's foundation on the new treatment in ovarian cancer.
  • Expression of MKP-1 and p-ERK(1/2) in tissues from 64 patients with primary ovarian epithelial tumor, 35 patients with ovarian epithelial bordline tumor, 32 patients with ovarian epithelial benign tumor and 26 normal ovarian tissues was detected by immunohistochemistry.
  • Immunohistochemistry and Western-blot assay showed that the expression of MKP-1 was gradually decreased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were significant differences among them (P < 0.01).
  • However, the expression of p-ERK(1/2) was gradually increased in normal ovarian tissues, benign tumor, bordline tumor and carcinoma respectively, and there were also significant differences among them (P < 0.01), the p-ERK(1/2) expression level in the carcinoma tissues of stage III/IV patients was significantly higher than that of stage I/II patients.
  • Expression of MKP-1 and p-ERK(1/2) in same ovarian carcinoma tissues detected by immunohistochemistry and Western-blot assay showed significant negative correlation (r = -0.90, P < 0.01 and r = -0.78, P < 0.01 respectively).
  • The expression changes of MKP-1 and ERKs may play a role in the development of ovarian carcinoma.
  • The abnormal expression of MKP-1 and p-ERK(1/2) probably assists in promoting the development and progression of ovarian carcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697705.001).
  • [ISSN] 1673-520X
  • [Journal-full-title] Fen zi xi bao sheng wu xue bao = Journal of molecular cell biology
  • [ISO-abbreviation] Fen Zi Xi Bao Sheng Wu Xue Bao
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


15. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF: Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother; 2009 Sep;58(9):1375-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor expression in normal ovary and ovarian tumors.
  • Recent studies have implicated inflammation in the initiation and progression of ovarian cancer, though the mechanisms underlying this effect are still not clear.
  • Tumor cell expression of TLRs can promote inflammation and cell survival in the tumor microenvironment.
  • Here we sought to characterize the expression of TLRs in normal human ovaries, benign and malignant ovarian tumors from patients, and in established ovarian tumor cell lines.
  • We report that TLR2, TLR3, TLR4, and TLR5 are strongly expressed on the surface epithelium of normal ovaries.
  • TLR2, TLR3, TLR4, and TLR5 are expressed in benign conditions, epithelial tumors, and in ovarian cancer cell lines.
  • Variable expression of TLR6 and TLR8 was seen in benign and malignant epithelium of some patients, while expression of TLR1, TLR7, and TLR9 was weak.
  • Normal and malignant ovarian stroma were negative for TLR expression.
  • These studies demonstrate expression of multiple TLRs in the epithelium of normal ovaries and in ovarian tumor cells, and may indicate a mechanism by which epithelial tumors manipulate inflammatory pathways to facilitate tumor progression.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism. Toll-Like Receptors / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Epithelial Cells / metabolism. Estrous Cycle / metabolism. Female. Humans. Immunoenzyme Techniques. Mice. Mice, Inbred C57BL. Middle Aged. Prognosis. Tissue Array Analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184006.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Toll-Like Receptors
  •  go-up   go-down


16. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res; 2005 Nov 15;65(22):10602-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
  • Papillary serous low malignant potential (LMP) tumors are characterized by malignant features and metastatic potential yet display a benign clinical course.
  • The role of LMP tumors in the development of invasive epithelial cancer of the ovary is not clearly defined.
  • The aim of this study is to determine the relationships among LMP tumors and invasive ovarian cancers and identify genes contributing to their phenotypes.
  • Affymetrix U133 Plus 2.0 microarrays (Santa Clara, CA) were used to interrogate 80 microdissected serous LMP tumors and invasive ovarian malignancies along with 10 ovarian surface epithelium (OSE) brushings.
  • Gene expression profiles for each tumor class were used to complete unsupervised hierarchical clustering analyses and identify differentially expressed genes contributing to these associations.
  • The expression profiles of LMP, low-grade, and high-grade papillary serous ovarian carcinomas suggest that LMP tumors are distinct from high-grade cancers; however, they are remarkably similar to low-grade cancers.
  • Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype.
  • [MeSH-major] Carcinoma, Papillary / genetics. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Female. Gene Expression Profiling. Humans. Neoplasm Staging. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288054.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


17. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


18. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • Borderline tumors of all surface epithelial cell types have been studied.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


19. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • However, there were very few published data regarding the role of maspin in ovarian carcinoma.
  • The aim of the present study was to evaluate maspin expression in ovarian epithelial neoplasms and correlate its expression with some clinicopathologic parameters.
  • MATERIAL AND METHODS: Seventy eight paraffin embedded ovarian specimens from patients with ovarian epithelial neoplasms comprised the material of this study.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • On the other hand, 57.14% of LMP tumors showed weak maspin expression and 63% of malignant ovarian epithelial tumors showed maspin expression with 39.1% over expression.
  • CONCLUSION: Maspin was expressed in a substantial proportion of ovarian tumors with poor prognostic parameters.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Serine Proteinase Inhibitors / metabolism
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


20. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, Shiozawa T, Konishi I: Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med Mol Morphol; 2009 Jun;42(2):82-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression.
  • Changes in the expression of E-cadherin have been reported to be important in the tumorigenesis and progression of epithelial ovarian carcinoma.
  • To further examine the mechanisms regulating E-cadherin expression in ovarian tumorigenesis, we investigated the immunohistochemical expression of transcriptional repressors for E-cadherin, such as Snail, Slug, SIP1, and Twist, in the ovarian surface epithelium (OSE) and 95 cases of epithelial ovarian tumors.
  • Of 95 ovarian tumors, the expression of Snail, Slug, SIP1, and Twist increased stepwise in benign, borderline, and malignant tumors.
  • The prognosis of ovarian carcinoma patients positive for Snail expression was poorer than that of negative patients.
  • Our results indicate that the expression of E-cadherin transcriptional repressors increased with malignancy in ovarian epithelial neoplasms and that the expression of E-cadherin and its negative regulators is altered during ovarian cancer development and peritoneal dissemination.
  • [MeSH-major] Cadherins / metabolism. Carcinoma / metabolism. Ovarian Neoplasms / metabolism. Repressor Proteins / metabolism. Transcription Factors / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Blotting, Western. Disease Progression. Female. Humans. Immunohistochemistry. Nerve Tissue Proteins / analysis. Nerve Tissue Proteins / metabolism. Nuclear Proteins / analysis. Nuclear Proteins / metabolism. Ovary / chemistry. Ovary / cytology. Ovary / pathology. RNA-Binding Proteins / analysis. RNA-Binding Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Snail Family Transcription Factors. Twist-Related Protein 1 / analysis. Twist-Related Protein 1 / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1437-47 [14507651.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):922-8 [9269828.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12 (18):5369-76 [17000670.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24661-6 [11323412.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1469-76 [15619205.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):196-203 [17583745.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):180-8 [10188716.001]
  • [Cites] J Pathol. 2000 Dec;192(4):460-9 [11113863.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):98-101 [11857019.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):16-7 [10973239.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12 ):1816-22 [16773075.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):925-34 [17081918.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3241-6 [12082640.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Mar;21(1):65-71 [12071532.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):520-8 [17024425.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):314-20 [17211477.001]
  • [Cites] Clin Exp Metastasis. 2006;23(1):65-74 [16826427.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Mar;3(3):155-66 [11994736.001]
  • [Cites] Biol Rev Camb Philos Soc. 1996 Nov;71(4):529-43 [8923798.001]
  • [Cites] J Pathol. 1998 Jul;185(3):262-6 [9771479.001]
  • [Cites] Histopathology. 1998 Jan;32(1):69-80 [9522220.001]
  • [Cites] Curr Opin Oncol. 1994 Jan;6(1):106-13 [7515692.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Cell Cycle. 2006 Aug;5(16):1756-9 [16880738.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):329-39 [17487558.001]
  • (PMID = 19536615.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / GEMIN2 protein, human; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA-Binding Proteins; 0 / Repressor Proteins; 0 / SNAI1 protein, human; 0 / Snail Family Transcription Factors; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist-Related Protein 1
  •  go-up   go-down


21. Zhang S, Wei L, Zhang A, Zhang L, Yu H: RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS; 2009 Aug;13(4):307-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines.
  • RUNX3 is an important tumor suppressor gene located on human chromosome 1p36.1, and many tumors do not express it due to methylation of the promoter region of the CpG island.
  • The molecular mechanisms involved in RUNX3 gene expression and epithelial ovarian cancer are not fully understood.
  • This study investigates the relationship between RUNX3 methylation and expression in ovarian cancer.
  • The methylation of the RUNX3 gene promoter region was measured in 32 primary epithelial ovarian cancer samples and corresponding nonmalignant ovarian tissues, 36 benign epithelial ovarian tumor tissues, and 10 normal ovarian tissues by methylation-specific PCR (MSP) and RT-PCR.
  • We detected RUNX3 methylation in 53.1% of primary ovarian cancer tumors, 16.7% of benign ovarian tumors, and 28% of nonmalignant tissues surrounding ovarian cancers.
  • No methylation was detected in normal ovarian tissues.
  • The RT-PCR results found RUNX3 expression in all normal ovarian tissues (10/10) and in most of the unmethylated ovarian cancer tissues (12/15); in contrast, it was not detected in most of the RUNX3-methylated ovarian cancer tissues (16/17).
  • Our data suggest that methylation plays a critical role in the regulation of RUNX3 repression, and that it is significantly correlated with RUNX3 mRNA expression in ovarian cancer tissues (p = 0.006).
  • [MeSH-major] Core Binding Factor Alpha 3 Subunit / metabolism. DNA Methylation. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands. DNA Modification Methylases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Promoter Regions, Genetic. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645591.001).
  • [ISSN] 1557-8100
  • [Journal-full-title] Omics : a journal of integrative biology
  • [ISO-abbreviation] OMICS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / Enzyme Inhibitors; 0 / RNA, Messenger; 0 / Runx3 protein, human; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


22. Hopfer O, Zwahlen D, Fey MF, Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer; 2005 Sep 19;93(6):709-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Notch pathway in ovarian carcinomas and adenomas.
  • Elements of the Notch pathway regulate differentiation; we investigated the expression of such elements in epithelial ovarian tumours.
  • A total of 32 ovarian tumour samples (17 adenocarcinomas, three borderline tumours, 12 adenomas), two human ovarian cancer (A2780, OVCAR3), and one ovarian surface (IOSE 144) cell lines were analysed.
  • Quantitative PCR revealed decreased Notch 1 mRNA in ovarian adenocarcinomas compared with adenomas.
  • The expression of Notch 1-EC protein was similar in benign and malignant tumours.
  • HES1 protein was strongly expressed in 18/19 ovarian cancers and borderline tumours but not in adenomas.
  • Thus, Notch pathway elements are expressed in ovarian epithelial tumours and some of them are differentially expressed between adenomas and carcinomas.
  • The Notch pathway could be a target for the development of therapies for ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Membrane Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basic Helix-Loop-Helix Transcription Factors. Cell Proliferation. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Middle Aged. Ovary / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Notch. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1099-102 [10584867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):66-70 [10962441.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4191-8 [10980592.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1131-9 [11078798.001]
  • [Cites] Curr Opin Mol Ther. 2000 Feb;2(1):55-65 [11249652.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2609-22 [7590239.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14110-4 [9162037.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2077-88 [9528780.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9 [9874798.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2431-48 [10194420.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2803-11 [10329626.001]
  • [Cites] J Cell Physiol. 1999 Dec;181(3):393-409 [10528225.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):375-87 [15706405.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7291-7 [11585768.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):719-24 [11641404.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8342-57 [11840327.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1165-74 [12393852.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):137-44 [12515548.001]
  • [Cites] FASEB J. 2003 Jan;17(1):79-81 [12424225.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1777-83 [12406868.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1988-97 [12673204.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6694-701 [12944493.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1537-47 [2697181.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Blood. 1992 Feb 15;79(4):981-9 [1737106.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):828-33 [1544716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Biochem J. 2000 May 1;347 Pt 3:719-24 [10769175.001]
  • (PMID = 16136053.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 149348-15-2 / HES1 protein, human
  • [Other-IDs] NLM/ PMC2361628
  •  go-up   go-down


23. Zhu Y, Brännström M, Janson PO, Sundfeldt K: Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer; 2006 Apr 15;118(8):1884-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
  • Human ovarian surface epithelium (OSE), regarded as the precursor cell of epithelial ovarian adenocarcinoma, is not a fully developed epithelium when situated on the ovarian surface.
  • It lacks epithelial characteristics such as the cell-cell adhesion factor epithelial (E)-cadherin, but as we have shown earlier, this OSE can form functional tight junctions (TJs) in culture.
  • Recent gene-expression data on ovarian adenocarcinoma has pointed out a family of TJ proteins, the claudins, to be highly expressed in malignant compared to benign ovarian tumours.
  • The purpose of this study was to investigate the distribution of claudin 1-5 proteins in cultured OSE (n=4), normal ovarian (n=11), benign (n=8), borderline (n=7) and ovarian cancer (n=22) tissues.
  • We found that a weak or absence of expression of claudin 3 and claudin 4 in surface OSE changed to typical cell-border localisation in OSE of inclusion cysts in the normal ovarian stroma.
  • Semiquantitative estimations of immunoblots showed that claudin 3 was significantly increased in ovarian adenocarcinomas compared to benign and borderline-type tumours.
  • Claudin 4 was significantly increased in both borderline-type and ovarian adenocarcinomas compared to benign tumours, whereas no changes were found for claudin 1 or 5.
  • We conclude that both claudin 3 and 4, even though they differ in expression during ovarian malignant transformation, might be used as novel markers for ovarian tumours.
  • [MeSH-major] Adenocarcinoma / genetics. Membrane Proteins / biosynthesis. Ovarian Cysts / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Claudin-1. Claudin-3. Claudin-4. Claudin-5. Epithelium. Female. Gene Expression Profiling. Humans. Immunoblotting. Ovary / physiology. Phenotype. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16287068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


24. Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol; 2010;8:147
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent data provide significant evidence to support the hypothesis that there are sub-populations of cells within solid tumors that have an increased tumor initiating potential relative to the total tumor population.
  • CD133, a cell surface marker expressed on primitive cells of neural, hematopoietic, endothelial and epithelial lineages has been identified as a marker for tumor initiating cells in solid tumors of the brain, colon, pancreas, ovary and endometrium.
  • In addition, we confirmed the tumor initiating potential of CD133+ and CD133- cell fractions in NOD/SCID mice.
  • Interestingly, the percentage of CD133+ cells in human endometrial tumor xenografts, as evidenced by immunofluorescence, increased with serial transplantation although this trend was not consistently detected by flow cytometry.
  • To support this finding, we demonstrated that regions of the CD133 promoter were hypomethylated in malignant endometrial tissue relative to benign control endometrial tissue.
  • Lastly, we determined that methylation of the CD133 promoter decreases over serial transplantation of an endometrial tumor xenograft.
  • [MeSH-minor] Animals. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Res. 2008 Oct;18(10):1037-46 [18679414.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8094-103 [18829568.001]
  • [Cites] Cell Cycle. 2009 Jan 1;8(1):158-66 [19158483.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Biol Reprod. 2009 Jun;80(6):1136-45 [19228591.001]
  • [Cites] Anticancer Res. 2009 Jun;29(6):2235-7 [19528487.001]
  • [Cites] Clin Cancer Res. 2009 Jul 1;15(13):4299-311 [19509143.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] BMC Cancer. 2009;9:221 [19583859.001]
  • [Cites] Cancer Res. 2009 Nov 1;69(21):8241-8 [19843861.001]
  • [Cites] Stem Cells. 2009 Oct;27(10):2405-13 [19658191.001]
  • [Cites] Stem Cells. 2009 Dec;27(12):2875-83 [19816957.001]
  • [Cites] J Biochem. 2010 Sep;148(3):273-80 [20551139.001]
  • [Cites] Hum Pathol. 2010 Nov;41(11):1516-29 [20800872.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):213-23 [14747944.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):295-308 [10757340.001]
  • [Cites] Endocr Relat Cancer. 2000 Dec;7(4):227-42 [11174845.001]
  • [Cites] Breast Cancer Res. 2003;5(1):R1-8 [12559051.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2055-61 [14630820.001]
  • [Cites] Biol Reprod. 2004 Jun;70(6):1738-50 [14766732.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Biol Reprod. 1989 Mar;40(3):681-90 [2758097.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5002-12 [9389720.001]
  • [Cites] Blood. 1997 Dec 15;90(12):5013-21 [9389721.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Stem Cells. 2006 Jun;24(6):1529-38 [16456137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Hum Reprod. 2007 Jan;22(1):45-51 [16923745.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Hum Reprod. 2007 May;22(5):1214-23 [17283036.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):479-85 [17762575.001]
  • [Cites] Cell Cycle. 2008 Jan 15;7(2):242-9 [18256549.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):506-14 [17868344.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4311-20 [18519691.001]
  • [Cites] J Mol Med (Berl). 2008 Sep;86(9):1025-32 [18535813.001]
  • [Cites] Oncogene. 2009 Jan 15;28(2):209-18 [18836486.001]
  • (PMID = 21122138.001).
  • [ISSN] 1477-7827
  • [Journal-full-title] Reproductive biology and endocrinology : RB&E
  • [ISO-abbreviation] Reprod. Biol. Endocrinol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098258; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC3027593
  •  go-up   go-down


25. Esheba GE, Pate LL, Longacre TA: Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol; 2008 Apr;32(4):600-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
  • Clear cell carcinoma (CCC) of the ovary is the surface epithelial neoplasm most often confused with primitive germ cell tumors, particularly yolk sac tumor (YST) and dysgerminoma.
  • To investigate whether GPC3 is useful in distinguishing YST from ovarian CCC, we studied the expression of GPC3 in a large series of ovarian neoplasms and compared it to the expression profiles of CK7 and alpha-fetoprotein.
  • Tissue microarrays containing over 400 benign and malignant ovarian neoplasms, including 34 CCCs were stained with monoclonal GPC3 (clone 1G12, Biomosaics, Burlington, VT).
  • These arrays contained a wide assortment of ovarian surface epithelial neoplasms and sex cord stromal neoplasms, as well as germ cell tumors.
  • All but one YST (97%), including those associated with mixed germ cell tumor were positive for GPC3, whereas all teratomas and embryonal carcinomas were negative.
  • All other tissues, including normal ovary were negative for GPC3.
  • GPC3 seems to be a promising diagnostic marker for differentiating YST from ovarian CCC (P < 0.0001).
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma / chemistry. Endodermal Sinus Tumor / chemistry. Glypicans / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7 / analysis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277882.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / alpha-Fetoproteins; 0 / oncofetal antigens
  •  go-up   go-down


27. Temkin S, Nacharaju VL, Hellman M, Lee YC, Abulafia O: Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer. Steroids; 2006 Nov;71(11-12):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.
  • In the ovary cortisol-cortisone inter-conversion is catalyzed by the enzyme 11beta-hydroxysteroid dehydrogenase (11beta-HSD).
  • Its role in carcinomas of human ovary is unknown.
  • The majority of ovarian cancers are derived from ovarian surface epithelium and the inflammation caused by successive ovulation seems to a play a role in the development of cancer.
  • Cortisol is known to act as anti-inflammatory agent and its metabolism by type 1 and type 11beta-HSD may control the inflammatory action by cortisol in ovary.
  • We undertook this study to investigate type 2 11beta-HSD activity which functions exclusively oxidative direction, in normal ovarian tissue compared to ovarian epithelial cancer.
  • Ovarian tissue was obtained from patients undergoing hysterectomy for both benign and malignant disease.
  • Mean type 2 enzyme activity was 0.87 +/- 1.65 pmol/min g tissue in normal ovarian tissue versus a mean enzyme activity of 2.96 +/- 1.37 pmol/mim g tissue in from cancer specimens.
  • Type 2 1beta-HSD activity in ovarian cancer specimens was significantly higher than enzyme activity measured in normal post-menopausal ovarian tissue.
  • Decreased cortisol levels due type 2 1beta-HSD activity may play a role neoplastic transformation as well as tumor proliferation in ovarian cancer by eliminating anti-inflammatory action of cortisol.
  • [MeSH-major] 11-beta-Hydroxysteroid Dehydrogenase Type 2 / metabolism. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Aged. Female. Humans. Isoenzymes / metabolism. Menopause. Middle Aged. Ovary / enzymology. Ovary / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028049.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.1.1.146 / 11-beta-Hydroxysteroid Dehydrogenase Type 2
  •  go-up   go-down


28. Lewis MR, Deavers MT, Silva EG, Malpica A: Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol; 2006 Feb;30(2):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge.
  • Ovarian involvement by metastatic colorectal adenocarcinoma, although not an uncommon occurrence, remains a diagnostic challenge.
  • The gross and histologic features of such metastases overlap those of primary ovarian epithelial neoplasms such as endometrioid or mucinous adenocarcinoma.
  • The clinical and pathologic features of 86 cases of metastatic colorectal adenocarcinoma involving the ovary were reviewed.
  • In 23 cases, an ovarian mass was the first manifestation of the disease.
  • Ovarian involvement was bilateral in 49 cases and unilateral in 33 (including 20 cases in which the only involved ovary measured at least 10 cm in greatest dimension).
  • Many involved ovaries featured smooth capsules without gross evidence of surface involvement by tumor.
  • In 23 cases, foci with a benign or low malignant potential appearance were seen.
  • In 9 of the cases, an ovarian primary was diagnosed or favored initially, and 5 of these cases were initially treated as ovarian primaries.
  • Metastatic colorectal adenocarcinoma should be considered in the differential diagnosis of an ovarian mass, even if the mass is large and unilateral or in a young patient, to secure proper treatment of these patients.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434891.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • Nonsmall cell neuroendocrine carcinoma (NSCNEC) of the ovary is a rare and aggressive tumor commonly associated with other surface epithelial and germ cell neoplasms.
  • In 8 cases, NSCNEC was associated with other epithelial neoplasms, including mucinous neoplasms of low malignant potential, mucinous carcinoma, endometrioid carcinoma, mixed endometrioid and mucinous carcinoma, and a high-grade carcinoma, not otherwise specified.
  • In 2 cases, the tumor was associated with a mature cystic teratoma; one of them also containing an invasive moderately differentiated adenocarcinoma.
  • A single case was associated with a benign ovarian cyst.
  • The latter case had a dermoid cyst in the contralateral ovary.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


30. Noske A, Denkert C, Schober H, Sers C, Zhumabayeva B, Weichert W, Dietel M, Wiechen K: Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer; 2005 Feb;41(3):461-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of Gelsolin expression in human ovarian carcinomas.
  • In the present study, we analysed the expression of gelsolin in 241 matched cDNA pairs from human normal and tumour tissues using a Cancer Profiling Array.
  • We found a decreased expression of gelsolin in cancer tissue from female reproductive organs, including the ovary.
  • On a protein level, we examined the expression of gelsolin in human ovarian cancer cell lines and in a set of 110 cases of human benign and malignant ovarian tumours.
  • Low levels of gelsolin protein were observed in four of six ovarian carcinoma cell lines, in contrast to its expression in normal ovarian surface epithelial cells.
  • In addition, we found a reduced expression of gelsolin in borderline tumours and ovarian carcinomas compared with the epithelium of normal ovaries and benign adenomas.
  • In addition, we investigated the growth regulatory function of gelsolin in human ovarian cancer cell lines using cDNA transfections.
  • Re-expression of gelsolin in OAW42 and ES-2 cells resulted in a suppression of tumour cell survival in vitro.
  • To explore the mechanism responsible for the downregulation of gelsolin expression in ovarian carcinoma cells, we treated cells with inhibitors of DNA methylation and histone deacetylation.
  • We observed an upregulation of gelsolin in ovarian cancer cells after treatment with both types of inhibitor.
  • Our results suggest that gelsolin might be involved in the growth regulation of human ovarian cancer.
  • [MeSH-major] Gelsolin / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Down-Regulation. Female. Humans. Immunohistochemistry. Middle Aged. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691647.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin
  •  go-up   go-down


31. Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A: High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
  • The molecular etiology of epithelial ovarian cancer remains unclear.
  • Using microarray expression analysis, we recently reported that expression of the insulin-like growth factor binding protein-2 (IGFBP-2) gene is elevated in advanced epithelial ovarian cancers.
  • The aim of this study was to further delineate the role of IGFBP-2 in the pathoetiology of epithelial ovarian cancer and determine if elevated ovarian cancer IGFBP-2 gene expression is reflected in serum.
  • Relative IGFBP-2 expression was measured using quantitative real-time polymerase chain reaction in 113 epithelial ovarian cancers and 6 normal ovarian surface epithelial samples.
  • Preoperative serum IGFBP-2 levels were measured by radioimmunoassay in 84 women (42 ovarian cancers, 26 benign gynecological conditions, and 10 healthy female controls).
  • Ovarian cancers demonstrated 38-fold higher mean IGFBP-2 expression than normal ovarian epithelium (P < 0.01).
  • Serum IGFBP-2 levels were elevated in women with early- and advanced-stage ovarian cancer compared to controls and patients with benign gynecological conditions (P = 0.05 and P < 0.01, respectively).
  • Epithelial ovarian cancers express high levels of IGFBP-2 relative to normal ovarian epithelium, and this is associated with elevated serum IGFBP-2 levels compared to both normal controls and patients with benign gynecological disease.
  • Our findings provide further support that the insulin-like growth factor pathway plays a significant role in epithelial ovarian cancer pathogenesis.
  • Further, IGFBP-2 may represent an additional serum biomarker with utility in detection and monitoring of epithelial ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Gene Expression Regulation, Neoplastic / genetics. Insulin-Like Growth Factor Binding Protein 2 / blood. Neoplasms, Glandular and Epithelial / blood. Ovarian Neoplasms / blood. RNA, Messenger / blood
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / surgery. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / surgery. CA-125 Antigen / blood. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / surgery. Endometrial Neoplasms / blood. Endometrial Neoplasms / genetics. Endometrial Neoplasms / surgery. Female. Humans. Immunoenzyme Techniques. Neoplasm Staging. Ovarian Cysts / blood. Ovarian Cysts / genetics. Ovary / pathology. Precancerous Conditions / blood. Precancerous Conditions / genetics. Precancerous Conditions / surgery. Preoperative Care. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884361.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / RNA, Messenger
  •  go-up   go-down


32. Ota T, Klausen C, Salamanca MC, Woo HL, Leung PC, Auersperg N: Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells. Differentiation; 2009 Feb;77(2):162-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.
  • We studied the roles of three HOXA genes in cultured normal ovarian surface epithelial (OSE) cells and ovarian cancer cells.
  • They included HOXA4 and HOXA7 because, by cDNA microarray analysis, these were more highly expressed in invasive ovarian carcinomas than in benign or borderline (noninvasive) ovarian tumors, and HOXA9 because it characterizes normal oviductal epithelium, which resembles ovarian serous adenocarcinomas.
  • The expression of the HOXA genes varied among ovarian cancer cell lines, but was highest in lines with compact epithelial morphologies.
  • We focused on HOXA4 as the most highly expressed in the ovarian carcinoma array.
  • HOXA4 expression did not parallel proliferative activities of either OSE or ovarian cancer lines.
  • Moreover, modifying HOXA4 expression in ovarian cancer cell lines did not alter either E-cadherin expression or CA125 secretion.
  • However, HOXA4 downregulation enhanced EGFR phosphorylation and migration in serum-starved OSE and ovarian cancer cells in response to EGF, and enhanced migration of all ovarian cancer lines in 5% serum even without EGF treatment.
  • Thus, HOXA4 expression does not correlate with proliferation or with epithelial differentiation, but it increases in response to OSE cell dispersion and negatively regulates EGFR activation and the motility of OSE and of ovarian cancer cells.
  • HOXA4 expression was highest in cancer lines with compact epithelial growth patterns, suggesting, again, an anti-dispersion function.
  • In summary, increased HOXA4 expression in ovarian cancer appears to constitute a tumor-suppressive, homeostatic response to aberrant cell behavior, and, in particular, to cell dispersion and migration.
  • [MeSH-major] Epithelial Cells / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Cell Differentiation. Cell Line, Tumor. Cells, Cultured. Down-Regulation. Female. Gene Expression Regulation. Humans. Middle Aged. Ovary / cytology. Ovary / metabolism. Reference Standards. Reverse Transcriptase Polymerase Chain Reaction






Advertisement